Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases

Seminars in Nuclear Medicine

Volumn 39, Issue 6, 2009, Pages 416-430

  Chua, Sue ^a   Gnanasegaran, Gopinath ^b   Cook, Gary J R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN DERIVATIVE; TRACER;

BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CELL METABOLISM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MYELOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID CARCINOMA;

BONE NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MULTIPLE MYELOMA; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70349431200     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.07.002     Document Type: Review

References (116)

1. Kosuda S., Kaji T., Yokoyama H., et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?. J Nucl Med 37 (1996) 975-978
2. Savelli G., Maffioli L., Maccauro M., et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 45 (2001) 27-37
3. Schmidt G.P., Schoenberg S.O., Schmid R., et al. Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17 (2007) 939-949
4. Bybel B., Brunken R.C., DiFilippo F.P., et al. SPECT/CT imaging: Clinical utility of an emerging technology. Radiographics 28 (2008) 1097-1113
5. Fogelman I., Cook G., Israel O., et al. Positron emission tomography and bone metastases. Semin Nucl Med 35 (2005) 135-142
6. Pezeshk P., Sadow C.A., Winalski C.S., et al. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Acad Radiol 13 (2006) 1011-1015
7. Blau M., Ganatra R., and Bender M.A. 18 F-fluoride for bone imaging. Semin Nucl Med 2 (1972) 31-37
8. Grant F.D., Fahey F.H., Packard A.B., et al. Skeletal PET with 18F-fluoride: Applying new technology to an old tracer. J Nucl Med 49 (2008) 68-78
9. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42 (2001) 1800-1804
10. Langsteger W., Heinisch M., and Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 (2006) 73-92
11. Even-Sapir E., Metser U., Flusser G., et al. Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45 (2004) 272-278
12. Even-Sapir E., Mishani E., Flusser G., et al. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 37 (2007) 462-469
13. Schirrmeister H., Arslandemir C., Glatting G., et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 31 (2004) 964-968
14. Schirrmeister H., Guhlmann A., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 40 (1999) 1623-1629
15. De Maeseneer M., Lenchik L., Everaert H., et al. Evaluation of lower back pain with bone scintigraphy and SPECT. Radiographics 19 (1999) 901-912
16. Baum R.P., Hellwig D., and Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: Lung cancer. Q J Nucl Med Mol Imaging 48 (2004) 119-142
17. Utsunomiya D., Shiraishi S., Imuta M., et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 238 (2006) 264-271
18. Vinjamuri M., Craig M., Campbell-Fontaine A., et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer?. Clin Lung Cancer 9 (2008) 30-34
19. Peterson J.J., Kransdorf M.J., and O'Connor M.I. Diagnosis of occult bone metastases: Positron emission tomography. Clin Orthop Relat Res 415 suppl (2003) S120-S128
20. Cheran S.K., Herndon J.E., and Patz E.F. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 44 (2004) 317-325
21. Algra P.R., Heimans J.J., Valk J., et al. Do metastases in vertebrae begin in the body or the pedicles?. Imaging study in 45 patients. AJR Am J Roentgenol 158 (1992) 1275-1279
22. Bruzzi J.F., Komaki R., Walsh G.L., et al. Imaging of non-small cell lung cancer of the superior sulcus. Part 2: Initial staging and assessment of resectability and therapeutic response. Radiographics 28 (2008) 561-572
23. Zhu X.-x., Chen Y.-q., and Chen L.-h. [Value of integrated positron-emission tomography and computed tomography in gross tumor volume delineation for radiotherapy for bone metastasis]. Di Yi Jun Yi Xue Xue Bao 24 (2004) 700-702
24. Hetzel M., Arslandemir C., Konig H.-H., et al. F-18 NaF PET for detection of bone metastases in lung cancer: Accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 18 (2003) 2206-2214
25. Muresan M.M., Olivier P., Leclere J., et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15 (2008) 37-49
26. Tickoo S.K., Pittas A.G., Adler M., et al. Bone metastases from thyroid carcinoma: A histopathologic study with clinical correlates. Arch Pathol Lab Med 124 (2000) 1440-1447
27. Lin J.D., Huang M.J., Juang J.H., et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroidology 9 (1999) 1227-1235
28. Ruegemer J.J., Hay I.D., Bergstralh E.J., et al. Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67 (1988) 501-508
29. Schlumberger M., Tubiana M., De Vathaire F., et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63 (1986) 960-967
30. Ito S., Kato K., Ikeda M., et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48 (2007) 889-895
31. de Geus-Oei L.-F., Oei H.-Y., Hennemann G., et al. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 29 (2002) 768-774
32. Schirrmeister H., Buck A., Guhlmann A., et al. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroidology 11 (2001) 677-683
33. Shapiro B., Rufini V., Jarwan A., et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 30 (2000) 115-132
34. Ruf J., Lehmkuhl L., Bertram H., et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 25 (2004) 1177-1182
35. Zanotti-Fregonara P., Rubello D., and Hindie E. Bone metastases of differentiated thyroid cancer: The importance of early diagnosis and 131I therapy on prognosis. J Nucl Med 49 (2008) 1902-1903
36. Tharp K., Israel O., Hausmann J., et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 1435-1442
37. Conti P.S., Durski J.M., Bacqai F., et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroidology 9 (1999) 797-804
38. Grunwald F., Menzel C., Bender H., et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroidology 7 (1997) 327-335
39. Schluter B., Bohuslavizki K.H., Beyer W., et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42 (2001) 71-76
40. Grunwald F., Kalicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study. Eur J Nucl Med 26 (1999) 1547-1552
41. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 (2006) 498-505
42. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9 (2002) 913-921
43. Freudenberg L.S., Antoch G., Jentzen W., et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14 (2004) 2092-2098
44. Kollender Y., Bickels J., Price W.M., et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol 164 (2000) 1505-1508
45. Zekri J., Ahmed N., Coleman R.E., et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19 (2001) 379-382
46. Han K.-R., Pantuck A.J., Bui M.H.T., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61 (2003) 314-319
47. Mitchell M.S. Chemotherapy in combination with biomodulation: A 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol 19 (1992) 80-87
48. Hafez K.S., Novick A.C., and Campbell S.C. Patterns of tumor recurrence and guidelines for follow up after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 157 (1997) 2067-2070
49. Levy D.A., Slaton J.W., Swanson D.A., et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159 (1998) 1163-1167
50. Sandock D.S., Seftel A.D., and Resnick M.I. A new protocol for the follow up of renal cell carcinoma based on pathological stage. J Urol 154 (1995) 28-31
51. Rosen P.R., and Murphy K.G. Bone scintigraphy in the initial staging of patients with renal-cell carcinoma: Concise communication. J Nucl Med 25 (1984) 289-291
52. Staudenherz A., Steiner B., Puig S., et al. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma?. Cancer 85 (1999) 153-155
53. Wu H.C., Yen R.F., Shen Y.Y., et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas-A preliminary report. J Cancer Res Clin Oncol 128 (2002) 503-506
54. Kang D.E., White R.L., Zuger J.H., et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171 (2004) 1806-1809
55. Bhargava P., Hanif M., and Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med 33 (2008) 894-895
56. Fonti R., Salvatore B., Quarantelli M., et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 49 (2008) 195-200
57. Bataille R., Chevalier J., Rossi M., et al. Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. Radiology 145 (1982) 801-804
58. D'Sa S., Abildgaard N., Tighe J., et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 137 (2007) 49-63
59. Chiu M.L., Kronauge J.F., and Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 31 (1990) 1646-1653
60. Alexandrakis M.G., Kyriakou D.S., Passam F.H., et al. Correlation between the uptake of Tc99m-sestamibi and prognostic factors in patients with multiple myeloma. Clin Lab Hematol 24 (2002) 155-159
61. Hung G.-U., Tsai C.-C., Tsai S.-C., et al. Comparison of Tc99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res 25 (2005) 4737-4741
62. Durie B.G.M. The role of anatomic and functional staging in myeloma: Description of Durie/salmon plus staging system. Eur J Cancer 42 (2006) 1539-1543
63. Kato T., Tsukamoto E., Nishioka T., et al. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med 25 (2000) 870-873
64. Schirrmeister H., Bommer M., Buck A.K., et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 29 (2002) 361-366
65. Bredella M.A., Steinbach L., Caputo G., et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 184 (2005) 1199-1204
66. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
67. Durie B.G.M., Kyle R.A., Belch A., et al. Myeloma management guidelines: A consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 4 (2003) 379-398
68. Dankerl A., Liebisch P., Glatting G., et al. Multiple myeloma: Molecular imaging with 11C-methionine PET/CT-Initial experience. Radiology 242 (2007) 498-508
69. Falini B., Canino S., Sacchi S., et al. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. Br J Haematol 69 (1988) 311-320
70. Kulke M.H., and Mayer R.J. Carcinoid tumors. N Engl J Med 340 (1999) 858-868
71. Oberg K. Neuroendocrine gastrointestinal tumors-A condensed overview of diagnosis and treatment. Ann Oncol 10 (1999) 3-8
72. Shebani K.O., Souba W.W., Finkelstein D.M., et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229 (1999) 815-821
73. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
74. Wallace S., Ajani J.A., Charnsangavej C., et al. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg 20 (1996) 147-156
75. Meijer W.G., van der Veer E., Jager P.L., et al. Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44 (2003) 184-191
76. Zuetenhorst J.M., Hoefnageli C.A., Boot H., et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 23 (2002) 735-741
77. Ross E.M., and Roberts W.C. The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 79 (1985) 339-354
78. Scarsbrook A.F., Ganeshan A., Statham J., et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 27 (2007) 455-477
79. Leboulleux S., Dromain C., Vataire A.L., et al. Prediction and diagnosis of bone metastases in well-differentiated gastroenteropancreatic endocrine cancer: A prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93 (2008) 3021-3028
80. Even-Sapir E., Keidar Z., Sachs J., et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 42 (2001) 998-1004
81. Krausz Y., Keidar Z., Kogan I., et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol (Oxf) 59 (2003) 565-573
82. Pfannenberg A.C., Eschmann S.M., Horger M., et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30 (2003) 835-843
83. Adams S., Baum R., Rink T., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 25 (1998) 79-83
84. Eriksson B., Orlefors H., Oberg K., et al. Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab 19 (2005) 311-324
85. Koopmans K.P., Neels O.C., Kema I.P., et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26 (2008) 1489-1495
86. Gabriel M., Decristoforo C., Kendler D., et al. 68Ga-dota-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48 (2007) 508-518
87. 3-octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol Imaging 32 (2005) s54
88. Lynn M.D., Braunstein E.M., and Shapiro B. Pheochromocytoma presenting as musculoskeletal pain from bone metastases. Skeletal Radiol 16 (1987) 552-555
89. Ilias I., and Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 37 (2005) 717-721
90. Krausz Y., and Israel O. Single-photon emission computed tomography/computed tomography in endocrinology. Semin Nucl Med 36 (2006) 267-274
91. Tenenbaum F., Lumbroso J., Schlumberger M., et al. Comparison of radiolabelled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36 (1995) 1-6
92. Kaltsas G., Korbonits M., Heintz E., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2001) 895-902
93. Ilias I., Yu J., Carrasquillo J.A., et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88 (2003) 4083-4087
94. Shulkin B.L., Wieland D.M., Schwaiger M., et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 33 (1992) 1125-1131
95. Shulkin B.L., Ilias I., Sisson J.C., et al. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci 1073 (2006) 374-382
96. Shulkin B.L., Thompson N.W., Shapiro B., et al. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology 212 (1999) 35-41
97. Mamede M., Carrasquillo J.A., Chen C.C., et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 27 (2006) 31-36
98. Bouvier J.F., Philip T., Chauvot P., et al. Pitfalls and solutions in neuroblastoma diagnosis using radioiodine MIBG: Our experience about 50 cases. Prog Clin Biol Res 271 (1988) 707-720
99. Sofka C.M., Semelka R.C., Kelekis N.L., et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging 17 (1999) 193-198
100. Boubaker A., and Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 47 (2003) 31-40
101. Taggart D., Dubois S., and Matthay K.K. Radiolabelled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 52 (2008) 403-418
102. Barai S., Bandopadhayaya G.P., Malhotra A., et al. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma?. J Postgrad Med 50 (2004) 257-260
103. Cheung N.-K.V., and Kushner B.H. Should we replace bone scintigraphy plus CT with MR imaging for staging of neuroblastoma?. Radiology 226 (2003) 286-287
104. Shulkin B.L., and Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 39 (1998) 679-688
105. Dowell H.M., Losty P., Barnes N., et al. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 52 (2008) 552
106. Shulkin B.L., Wieland D.M., Baro M.E., et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37 (1996) 16-21
107. Cohen R., Campos J.M., Salaun C., et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'etudes des tumeurs a calcitonin (GETC). J Clin Endocrinol Metab 85 (2000) 919-922
108. Perault C., Schvartz C., Wampach H., et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The group of thyroid tumoral pathology of Champagne-Ardenne. J Nucl Med 38 (1997) 1234-1242
109. de Groot J.W., Links T.P., Jager P.L., et al. Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11 (2004) 786-794
110. Diehl M., Risse J.H., Brandt-Mainz K., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicenter study. Eur J Nucl Med 28 (2001) 1671-1676
111. Giraudet A.L., Vanel D., Leboulleux S., et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92 (2007) 4185-4190
112. Shammas A., Degirmenci B., Mountz J.M., et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48 (2007) 221-226
113. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: What is the impact of each modality?. Eur J Nucl Med Mol Imaging 34 (2007) 487-495
114. Zuijdwijk M.D., Vogel W.V., Corstens F.H.M., et al. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun 29 (2008) 636-641
115. Iagaru A., Kalinyak J.E., and McDougall I.R. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32 (2007) 690-695
116. Brandt-Mainz K., Muller S.P., Gorges R., et al. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 27 (2000) 490-496